Compound index

Incretin & Metabolic Receptor Agonists

Retatrutide

Also known as LY3437943

Late-stage human trialsInvestigational

Last reviewed: 2026-11-19

History

Eli Lilly developed LY3437943; early clinical reports appeared in 2022 and phase 2 results in 2023.

Key sources

Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.

Related compounds

  • Semaglutide

    Same scientific class · A 31-amino-acid chain. · FDA-approved for specific indications

  • Tirzepatide

    Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications

Related glossary terms